AVNS VS BCRX Stock Comparison
Performance
AVNS10/100
10/100
AVNS returned -19.03% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
BCRX10/100
10/100
BCRX returned -61.96% in the last 12 months. Based on SPY's performance of -21.29%, its performance is below average giving it a score of 10 of 100.
Sentiment
AVNS86/100
86/100
AVNS had a bullish sentiment score of 85.83% across Twitter and StockTwits over the last 12 months. It had an average of 1.00 posts, 0.00 comments, and 0.00 likes per day.
BCRX72/100
72/100
BCRX had a bullish sentiment score of 71.62% across Twitter and StockTwits over the last 12 months. It had an average of 71.07 posts, 220.44 comments, and 574.60 likes per day.
Technicals
AVNS61/100
61/100
AVNS receives a 60 of 100 based on 14 indicators. 8 are bullish, 5 are bearish.
BCRX14/100
14/100
BCRX receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
Earnings
AVNS10/100
10/100
AVNS has missed earnings 6 times in the last 20 quarters.
BCRX10/100
10/100
BCRX has missed earnings 10 times in the last 20 quarters.
Profit
AVNS46/100
46/100
Out of the last 20 quarters, AVNS has had 8 profitable quarters and has increased their profits year over year on 7 of them.
BCRX10/100
10/100
Out of the last 20 quarters, BCRX has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
AVNS46/100
46/100
AVNS has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.
BCRX49/100
49/100
BCRX has had a lower than average amount of volatility over the last 12 months giving it a score of 49 of 100.
Analyst Price Targets
AVNS
"Analyst Price Targets" not found for AVNS
BCRX70/100
70/100
10 analysts offer 12-month price targets for BCRX. Together, they have an average target of 19, the most optimistic target put BCRX at 25 within 12-months and the most pessimistic has BCRX at 14.
All score calculations are broken down here to help you make more informed investing decisions
Avanos Medical, Inc. Summary
New York Stock Exchange / AVNS
Healthcare
Medical - Devices
Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
BioCryst Pharmaceuticals Inc Summary
Nasdaq / BCRX
Healthcare
Biotechnology
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare AVNS to other companies in the same or a similar industry.